Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Petra Nytrová"'
Autor:
Petra Nytrova, Ondrej Dolezal
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
This review is a condensed summary of representative articles addressing the sex/gender bias in multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). The strong effects of sex on the incidence and possibly also the activity and
Externí odkaz:
https://doaj.org/article/b61a1b43c44a43818d22ef3905e462ad
Autor:
Kirsty E. Waddington, Artemis Papadaki, Leda Coelewij, Marsilio Adriani, Petra Nytrova, Eva Kubala Havrdova, Anna Fogdell-Hahn, Rachel Farrell, Pierre Dönnes, Inés Pineda-Torra, Elizabeth C. Jury
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Background: Neutralizing anti-drug antibodies (ADA) can greatly reduce the efficacy of biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the biological factors pre-disposing an individual to develop ADA are poorly chara
Externí odkaz:
https://doaj.org/article/3f18697f0ea04704bfe363826743d56e
Autor:
Letizia Granieri, Fabiana Marnetto, Paola Valentino, Jessica Frau, Agata Katia Patanella, Petra Nytrova, Patrizia Sola, Marco Capobianco, Sven Jarius, Antonio Bertolotto
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e38896 (2012)
BACKGROUND: Neuromyelitis optica (NMO) is a severely disabling autoimmune disorder of the central nervous system, which predominantly affects the optic nerves and spinal cord. In a majority of cases, NMO is associated with antibodies to aquaporin-4 (
Externí odkaz:
https://doaj.org/article/9ba79b35c52c42adab8f53bcb35d66b5
Autor:
Petra Kovalská, Simona Dostálová, Hana Machová, Petra Nytrová, Eszter Maurovich Horvat, Karel Šonka
Publikováno v:
Case Reports in Neurology, Vol 12, Iss 3, Pp 428-432 (2020)
A 69-year-old male developed symptoms typical of the diagnosis of narcolepsy type 1 without any previous triggering events. First, daytime sleepiness occurred, soon followed by cataplexy. Nocturnal polysomnography revealed rapid eye movement (REM) sl
Externí odkaz:
https://doaj.org/article/900b9eb08b1441e29dea5d70d9221bde
Autor:
Maryam Golshani, Ludmila Maffei Svobodová, Lubomír Štěpánek, Jan Zeman, Petra Nytrová, Helena Posová, Petra Petrásková, Olga Novotná, Michaela Nováková, Viktor Černý, Jiří Beneš, Libuše Kolářová, Martin Vokurka, Jiří Hrdý
Publikováno v:
Vaccines, Vol 10, Iss 12, p 2038 (2022)
Background: COVID-19 pandemic has led to a loss of human life in millions and devastating socio-economic consequences worldwide. So far, vaccination is the most effective long-term strategy to control and prevent severe COVID-19 disease. The aim of t
Externí odkaz:
https://doaj.org/article/6a6b6ff52f59481797d91f4a759fb8f1
Autor:
Manuela Vaněčková, Petra Nytrová
Publikováno v:
Česká a slovenská neurologie a neurochirurgie.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fab82de0422740c01d7c0cba85561058
https://doi.org/10.48095/cccsnn2022330
https://doi.org/10.48095/cccsnn2022330
Autor:
Alexandra E. Oppong, Leda Coelewij, Georgia Robertson, Lucia Martin-Gutierrez, Kirsty E. Waddington, Pierre Dönnes, Petra Nytrova, Rachel Farrell, Inés Pineda-Torra, Elizabeth C. Jury
Publikováno v:
iScience, Vol 27, Iss 3, Pp 109225- (2024)
Summary: There are no blood-based biomarkers distinguishing patients with relapsing-remitting (RRMS) from secondary progressive multiple sclerosis (SPMS) although evidence supports metabolomic changes according to MS disease severity. Here machine le
Externí odkaz:
https://doaj.org/article/71777b4f62664398a66e0208bc11171f
Autor:
Ragnhild Reehorst Lereim, Petra Nytrova, Astrid Guldbrandsen, Eva Kubala Havrdova, Kjell-Morten Myhr, Harald Barsnes, Frode S Berven
Publikováno v:
PLoS ONE, Vol 19, Iss 3, p e0300914 (2024)
BackgroundMultiple sclerosis is an inflammatory and degenerative disease of the central nervous system leading to demyelination and axonal loss. Relapsing-remitting multiple sclerosis (RRMS) is commonly treated by anti-inflammatory drugs, where one o
Externí odkaz:
https://doaj.org/article/6f42bd6b46a240189c2680da823bc02c
Autor:
Petra Nytrova, Dominika Stastna, Adam Tesar, Ingrid Menkyova, Helena Posova, Helena Koprivova, Veronika Mikulova, Jiri Hrdy, Gabriela Smela, Dana Horakova, Irena Rysankova, Kristyna Doleckova, Michaela Tyblova
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundRituximab (RTX) and ocrelizumab (OCR), B cell-depleting therapy targeting CD20 molecules, affect the humoral immune response after vaccination. How these therapies influence T-cell-mediated immune response against SARS-CoV-2 after immunizat
Externí odkaz:
https://doaj.org/article/fd83e3caa4d14846b4d386ffddd286ce
Autor:
Signe Hässler, Delphine Bachelet, Julianne Duhaze, Natacha Szely, Aude Gleizes, Salima Hacein-Bey Abina, Orhan Aktas, Michael Auer, Jerôme Avouac, Mary Birchler, Yoram Bouhnik, Olivier Brocq, Dorothea Buck-Martin, Guillaume Cadiot, Franck Carbonnel, Yehuda Chowers, Manuel Comabella, Tobias Derfuss, Niek De Vries, Naoimh Donnellan, Abiba Doukani, Michael Guger, Hans-Peter Hartung, Eva Kubala Havrdova, Bernhard Hemmer, Tom Huizinga, Kathleen Ingenhoven, Poul Erik Hyldgaard-Jensen, Elizabeth C Jury, Michael Khalil, Bernd Kieseier, Anna Laurén, Raija Lindberg, Amy Loercher, Enrico Maggi, Jessica Manson, Claudia Mauri, Badreddine Mohand Oumoussa, Xavier Montalban, Maria Nachury, Petra Nytrova, Christophe Richez, Malin Ryner, Finn Sellebjerg, Claudia Sievers, Dan Sikkema, Martin Soubrier, Sophie Tourdot, Caroline Trang, Alessandra Vultaggio, Clemens Warnke, Sebastian Spindeldreher, Pierre Dönnes, Timothy P Hickling, Agnès Hincelin Mery, Matthieu Allez, Florian Deisenhammer, Anna Fogdell-Hahn, Xavier Mariette, Marc Pallardy, Philippe Broët, ABIRISK consortium
Publikováno v:
PLoS Medicine, Vol 17, Iss 10, p e1003348 (2020)
BackgroundBiopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidrug
Externí odkaz:
https://doaj.org/article/4a837373673e4bce970064eeadc29077